Stock Analiz

Lineage Cell Therapeutics, Inc. (LCTX) stock forecast and price target

Price $0.91 · data as of November 13, 2026

12-month price target

Average target$5.50
Upside / downside+501.4%
Analysts6
ConsensusStrong buy
Low $3.00Average $5.50High $9.00

Gold marker: average target · white marker: today’s price ($0.91)

Analyst ratings

Strong buy 1Buy 5Hold 1Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-0.09+58.5%$6M
Next fiscal year
ends December 31, 2027
$-0.11−22.2%$21M
Next quarter
ends December 31, 2026
$-0.04+0.0%$1M
Quarter after
ends March 31, 2027
$-0.03—$2M

Consensus of the analysts covering Lineage Cell Therapeutics, updated daily.

Frequently asked questions

What is the Lineage Cell Therapeutics stock price target?

The average 12-month target from 6 analysts is $5.50, 501.4% above the current price of $0.91 Targets range from $3.00 to $9.00.

Is Lineage Cell Therapeutics a buy according to analysts?

The consensus rating is “Strong buy” (1 strong buy, 5 buy, 1 hold). Ratings are opinions, not guarantees; this is not investment advice.

How much is Lineage Cell Therapeutics expected to earn?

Analysts expect EPS of $-0.09 for the fiscal year ending December 31, 2026 and $-0.11 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.